Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study

Background: During the peak of Coronavirus disease (COVID-19) pandemic in Thailand when the emergence of delta variant reduced the efficacy of inactivated vaccine, Thailand had abundance of inactivated vaccine but mRNA vaccine was not available and the supply of adenoviral-vectored vaccine was limit...

Full description

Bibliographic Details
Main Authors: Pawat Phuensan, Jarongkorn Sirimongkolkasem, Terapong Tantawichien, Jeerath Phannajit, Stephen J. Kerr, Pokrath Hansasuta, Prawat Chantharit, Adisorn Wongsa, Pusit Fuengfoo, Anutra Chittinandana, Kriengsak Vareesangthip, Methee Chayakulkeeree, Sureeporn Jangsirikul, Araya Schmidt, Kanyika Wanvimonsuk, Poramed Winichakoon, Rattagan Kajeekul, Wichai Prayoonwiwat, Rungsun Rerknimitr
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Heliyon
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023104543

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023104543

Similar Items